EGI
VYGR icon

EAM Global Investors’s Voyager Therapeutics VYGR Stock Holding History

EAM Global Investors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-224,825
Closed -$1.71M – 263
2022
Q1 		$1.71M Buy
+224,825
New +$1M 0.32% 170
2019
Q3 		– Sell
-49,878
Closed -$1.36M – 151
2019
Q2 		$1.36M Buy
+49,878
New +$1.14M 0.58% 99
2018
Q2 		– Sell
-36,037
Closed -$677K – 185
2018
Q1 		$677K Buy
+36,037
New +$779K 0.35% 132

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM Global Investors's VYGR Position: Q2 2022 in Review

EAM Global Investors sold out of Voyager Therapeutics (VYGR) in Q2 2022, closing a stake of 224,825 shares — an estimated $1.71M sold.

EAM Global Investors first reported a position in VYGR in Q1 2018 and held it in 3 quarters. The position peaked at $1.71M in Q1 2022. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2022.

  • EAM Global Investors reported no remaining Voyager Therapeutics position as of Q2 2022 after selling out during the quarter.
  • EAM Global Investors sold 224,825 Voyager Therapeutics shares in Q2 2022, an estimated $1.71M.
  • EAM Global Investors first reported a position in Voyager Therapeutics in Q1 2018 and held it in 3 quarters.
  • EAM Global Investors's Voyager Therapeutics position peaked at $1.71M in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2022.

Based on EAM Global Investors's 13F filing for Q2 2022, filed 12 Aug 2022.